$AMRN Most likely scenarios (my own predictions & basis for investment) FYI only: 1) Label expansion of both primary (based on 9-5-2 AdCom positive vote & latest science) & secondary (based on 16-0 AdCom positive vote) granted; 2) IP issue is now already very narrow & no invality arguments for generics anymore, AMRN in driver's seat & settlement expected. 3) Trigs of low thresthhold of 135 on label or no specifc trigs limit but only as a risk factor & AMRN needs post approval study to provide supplemental clinical data complementary to ReduceIt, per negotiation of AMRN with FDA. 4) SP reaches 36+ eoy
  • 16
  • 4